Comparison of the Widening Capacities of Erythropoietin and U-74389g Concerning Platelet Distribution Width Levels

This study calculated the widening capacities of 2 drugs: the erythropoietin (Epo) and the antioxidant drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the platelet distribution width (PDW) levels augmentation, after the respective drug usage in an induced hypoxia reoxygenation animal experiment.

Materials and methods: The 2 main experimental endpoints at which the PDW levels (PDWl) were evaluated was the 60th reoxygenation min (for the groups A, C and E) and the 120th reoxygenation min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after U-74389G administration.

Results: The first preliminary study of Epo non significantly increased the PDWl by 0.39%+0.37% (pvalue=0.2830). Also, the second preliminary study of U-74389G significantly increased the PDWl by 0.97%+0.49% (p-value=0.0396). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has 2.458888-fold more widening potency than Epo (p-value=0.0000).

Conclusions: The anti-oxidant capacities of U-74389G enhance the acute widening properties; presenting 2.458888-fold wider on PDWl than epo (p-value=0.0000). 

Keywords: hypoxia; erythropoietin; U-74389G; platelet distribution width levels; re-oxygenation.